Manatt Health January 27, 2020
Helen R. Pfister

Editor’s Note: In a recent webinar, Manatt explained the complexities of the 340B program, which requires drug manufacturers to provide outpatient drugs to eligible healthcare entities at sharply reduced prices. The webinar also reviewed key findings from Manatt’s 50-state survey on the interplay between the 340B and Medicaid programs. In part one of our article summarizing the webinar, below, we review the 340B and Medicaid Drug Rebate Programs, as well as examine the interplay between 340B and Medicaid. Watch for part two of our summary in the February “Health Update,” sharing information on the 340B program’s growing scope, insights into two of 340B’s long-standing vulnerabilities, key findings from our 50-state 340B survey and a look forward at what’s next. Click...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Insurance, Medicaid, Pharma, Provider
Pfizer shifts creative to Publicis in latest marketing move
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Understanding the politics of drug pricing in the United States
FDA approves Akebia anemia pill, two years after rejection

Share This Article